185 related articles for article (PubMed ID: 3019702)
1. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Böhm RO; van Baak MA; Rahn KH
Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA
Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041
[TBL] [Abstract][Full Text] [Related]
4. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
[TBL] [Abstract][Full Text] [Related]
5. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.
Stumpe KO; Overlack A; Kolloch R; Schatz J; Witte PU; Pahnke K
Klin Wochenschr; 1986 Jun; 64(12):558-62. PubMed ID: 3016405
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
Predel HG; Düsing R; Bäcker A; Kipnowski J; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):143D-148D. PubMed ID: 3034023
[TBL] [Abstract][Full Text] [Related]
7. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
Iimura O; Shimamoto K
Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
[TBL] [Abstract][Full Text] [Related]
8. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.
Manhem PJ; Ball SG; Morton JJ; Murray GD; Leckie BJ; Fraser R; Robertson JI
Br J Clin Pharmacol; 1985 Jul; 20(1):27-35. PubMed ID: 2992562
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term effects of ramipril in hypertension.
de Leeuw PW; Birkenhäger WH
Am J Cardiol; 1987 Apr; 59(10):79D-82D. PubMed ID: 3034038
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of ramipril.
Ball SG; Robertson JI
Am J Cardiol; 1987 Apr; 59(10):23D-27D. PubMed ID: 3034028
[TBL] [Abstract][Full Text] [Related]
11. Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.
Tochikubo O; Asahina S; Kaneko Y
Am J Cardiol; 1987 Apr; 59(10):83D-85D. PubMed ID: 3034039
[TBL] [Abstract][Full Text] [Related]
12. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.
Kaneko Y; Omae T; Yoshinaga K; Iimura O; Inagaki Y; Ishii M; Saruta T; Yamada K; Kumahara Y; Ito K
Am J Cardiol; 1987 Apr; 59(10):86D-91D. PubMed ID: 3034040
[TBL] [Abstract][Full Text] [Related]
13. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
14. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
de Leeuw PW; Lugtenburg PL; van Houten H; Looman JH; Birkenhäger WH
J Cardiovasc Pharmacol; 1985; 7(6):1161-5. PubMed ID: 2418304
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).
Unger T; Moursi M; Ganten D; Hermann K; Lang RE
J Cardiovasc Pharmacol; 1986; 8(2):276-85. PubMed ID: 2422465
[TBL] [Abstract][Full Text] [Related]
16. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.
Vasmant D; Bender N
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S46-52. PubMed ID: 2483429
[TBL] [Abstract][Full Text] [Related]
17. Ramipril for hypertension secondary to renal artery stenosis. Changes in blood pressure, the renin-angiotensin system and total and divided renal function.
Tillman DM; Adams FG; Gillen G; Morton JJ; Robertson JI
Am J Cardiol; 1987 Apr; 59(10):133D-142D. PubMed ID: 3034022
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats.
Moursi MG; Ganten D; Lang RE; Unger T
J Hypertens Suppl; 1986 Oct; 4(3):S495-8. PubMed ID: 3023591
[TBL] [Abstract][Full Text] [Related]
19. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.
Villamil AS; Cairns V; Witte PU; Bertolasi CA
Am J Cardiol; 1987 Apr; 59(10):110D-114D. PubMed ID: 3034017
[TBL] [Abstract][Full Text] [Related]
20. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
Felder K; Witte PU
Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
